The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Posts
Vorasidenib, acquired from Agios in a $1.8 billion deal, slowed the growth of a certain type of low-grade glioma by 61% in a Phase III trial.
Could WuXi AppTec and Pfizer-backed CStone Pharmaceuticals be snapped up by a larger pharma company? Rumors are circulating that executives with the China-based company are exploring strategic options that could include a sale of the company.
